Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 310

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies

Open access
Bergeri, Isabel, Whelan, Mairead G., Ware, Harriet, Subissi, Lorenzo, Nardone, Anthony, Lewis, Hannah C., Li, Zihan, Ma, Xiaomeng, Valenciano, Marta, Cheng, Brianna, Al Ariqi, Lubna, Rashidian, Arash, Okeibunor, Joseph, Azim, Tasnim, Wijesinghe, Pushpa, Le, Linh-Vi, Vaughan, Aisling, Pebody, Richard, Vicari, Andrea, Yan, Tingting, Yanes-Lane, Mercedes, Cao, Christian, Clifton, David A., Cheng, Matthew P., Papenburg, Jesse, Buckeridge, David, Bobrovitz, Niklas, Arora, Rahul K., Van Kerkhove, Maria D., Unity Studies Collaborator Group·2022·PLOS Medicine

Published version of a preprint

Abstract

Background: Our understanding of the global scale of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection remains incomplete: Routine surveillance data underestimate infection and cannot infer on population immunity; there is a predominance of asymptomatic infections, and uneven access to diagnostics. We meta-analyzed SARS-CoV-2 seroprevalence studies, standardized to those described in the World Health Organization’s Unity protocol (WHO Unity) for general population seroepidemiological studies, to estimate the extent of population infection and seropositivity to the virus 2 years into the pandemic. Methods and findings: We conducted a systematic review and meta-analysis, searching MEDLINE, Embase, Web of Science, preprints, and grey literature for SARS-CoV-2 seroprevalence published between January 1, 2020 and May 20, 2022. The review protocol is registered with PROSPERO (CRD42020183634). We included general population cross-sectional and cohort studies meeting an assay quality threshold (90% sensitivity, 97% specificity; exceptions for humanitarian settings). We excluded studies with an unclear or closed population sample frame. Eligible studies—those aligned with the WHO Unity protocol—were extracted and critically appraised in duplicate, with risk of bias evaluated using a modified Joanna Briggs Institute checklist. We meta-analyzed seroprevalence by country and month, pooling to estimate regional and global seroprevalence over time; compared seroprevalence from infection to confirmed cases to estimate underascertainment; meta-analyzed differences in seroprevalence between demographic subgroups such as age and sex; and identified national factors associated with seroprevalence using meta-regression. We identified 513 full texts reporting 965 distinct seroprevalence studies (41% low- and middle-income countries [LMICs]) sampling 5,346,069 participants between January 2020 and April 2022, including 459 low/moderate risk of bias studies with national/subnational scope in further analysis. By September 2021, global SARS-CoV-2 seroprevalence from infection or vaccination was 59.2%, 95% CI [56.1% to 62.2%]. Overall seroprevalence rose steeply in 2021 due to infection in some regions (e.g., 26.6% [24.6 to 28.8] to 86.7% [84.6% to 88.5%] in Africa in December 2021) and vaccination and infection in others (e.g., 9.6% [8.3% to 11.0%] in June 2020 to 95.9% [92.6% to 97.8%] in December 2021, in European high-income countries [HICs]). After the emergence of Omicron in March 2022, infection-induced seroprevalence rose to 47.9% [41.0% to 54.9%] in Europe HIC and 33.7% [31.6% to 36.0%] in Americas HIC. In 2021 Quarter Three (July to September), median seroprevalence to cumulative incidence ratios ranged from around 2:1 in the Americas and Europe HICs to over 100:1 in Africa (LMICs). Children 0 to 9 years and adults 60+ were at lower risk of seropositivity than adults 20 to 29 ( p < 0.001 and p = 0.005, respectively). In a multivariable model using prevaccination data, stringent public health and social measures were associated with lower seroprevalence ( p = 0.02). The main limitations of our methodology include that some estimates were driven by certain countries or populations being overrepresented. Conclusions: In this study, we observed that global seroprevalence has risen considerably over time and with regional variation; however, over one-third of the global population are seronegative to the SARS-CoV-2 virus. Our estimates of infections based on seroprevalence far exceed reported Coronavirus Disease 2019 (COVID-19) cases. Quality and standardized seroprevalence studies are essential to inform COVID-19 response, particularly in resource-limited regions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1004107

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Research works printed but not linked: 18

  1. N Bobrovitz, 2021, A systematic review and meta-analysis of SARS-CoV-2 seroprevalence studies aligned with the WHO population-based sero-epidemiological ‘Unity’ protocol CRD42020183634, PROSPERO
  2. SeroTracker Group, 2022, SeroTracker: Our Data (Our Protocol), Airtable
  3. COVID-19 Global Humanitarian Response Plan, 2020, United Nations Office for the Coordination of Humanitarian Affairs
  4. M Morgan, Sensitivity and specificity of multiple tests, In: Radiopaedia
  5. NRL, 2021, WHO COVID Evaluations Summary of Results, nrlquality
  6. HTG Aus AGD of, 2021, Post market review of COVID-19 point-of-care tests, Therapeutic Goods Administration (TGA). Australian Government Department of Health
  7. FIND, 2021, FIND evaluation of SARS-CoV-2 antibody (Ab) detection tests, FIND: Diagnosis for All
  8. N Bobrovitz, 2021, SeroTracker-ROB: reproducible decision rules for risk of bias assessment of seroprevalence studies, Epidemiology
  9. World Health Organization, 2021, Regional offices
  10. The World Bank, 2021, World Bank Country and Lending Groups
  11. World Health Organization, London School of Hygiene and Tropical Medicine, 2021, Public Health and Social Measures
  12. J Higgins, 2021, Cochrane Handbook for Systematic Reviews of Interventions (version 6.2), Cochrane
  13. WHO Headquarters (HQ), 2020, WHO COVID-19 Case definition
  14. H Ritchie, 2020, Coronavirus Pandemic (COVID-19), Our World in Data
  15. Institute for Health metrics and Evaluation (IHME), 2021, COVID-19: Estimating the historical time series of infections
  16. Institute for Health metrics and Evaluation (IHME), 2021, COVID-19 Estimates
  17. Puya-Dehgani-Mobaraki, 2022, Long-Term Persistence of IgG Antibodies in recovered COVID-19 individuals at 18 months and the impact of two-dose BNT162b2 (Pfizer-BioNTech) mRNA vaccination on the antibody response, Infectious Diseases (except HIV/AIDS)
  18. CJE Metcalf, 2017, Opportunities and challenges of a world serum bank–authors’ reply, Lancet, 389, 252, 10.1016/S0140-6736(17)30054-5 · doi:10.1016/s0140-6736(17)30054-5

Cited by

See all 310

Metadata

Authors
Bergeri, I., Whelan, M. G., Ware, H., Subissi, L., Nardone, A., Lewis, H. C., Li, Z., Ma, X., Valenciano, M., Cheng, B., Al Ariqi, L., Rashidian, A., Okeibunor, J., Azim, T., Wijesinghe, P., Le, L.-V., Vaughan, A., Pebody, R., Vicari, A., Yan, T., Yanes-Lane, M., Cao, C., Clifton, D. A., Cheng, M. P., Papenburg, J., Buckeridge, D., Bobrovitz, N., Arora, R. K., Van Kerkhove, M. D., & Unity Studies Collaborator Group
Venue
PLOS Medicine
Published
2022-11-10
Volume
19
Issue
11
Pages
e1004107
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W4308706077
Cited by
310
References
45
FWCI
13.72
Type
journal article
Language
en
Open access
gold
Funders
  • WHO COVID-19 Solidarity Response Fund
  • German Federal Ministry of Health COVID-19 Research and Development Fund
  • World Health Organisation
  • Canada’s COVID-19 Immunity Task Force through the Public Health Agency of Canada (2021-HQ-000056)
  • Canadian Medical Association Joule Innovation Fund
  • Robert Koch Institute

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. https://app.cochat.ai/papers/10.1371/journal.pmed.1004107
The paper
Bergeri, I., Whelan, M. G., Ware, H., Subissi, L., Nardone, A., Lewis, H. C., Li, Z., Ma, X., Valenciano, M., Cheng, B., Al Ariqi, L., Rashidian, A., Okeibunor, J., Azim, T., Wijesinghe, P., Le, L.-V., Vaughan, A., Pebody, R., Vicari, A., . . . Unity Studies Collaborator Group. (2022). Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1004107

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.